We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

50 hedge funds and large institutions have $10.5M invested in Cue Biopharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $24K | Put options by funds: $8K

0.01% more ownership

Funds ownership: 0.95% → 0.95% (+0.01%)

33% less funds holding

Funds holding: 75 → 50 (-25)

38% less capital invested

Capital invested by funds: $17.1M → $10.5M (-$6.59M)

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

89% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 28

Holders
50
Holders Change
-25
Holders Change %
-33.33%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
8
Reduced
17
Closed
28
Calls
$24K
Puts
$8K
Net Calls
+$16K
Net Calls Change
-$245K

Top Buyers

Rank Fund Capital Flow
1
BL
Bleichroeder LP
New York
+$1.54M
2
SPC
Sigma Planning Corp
Michigan
+$97.7K
3
GLA
Good Life Advisors
Pennsylvania
+$54.1K
4
XT
XTX Topco
Cayman Islands
+$20K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.8K

Top Sellers

Rank Fund Capital Flow
1
MAM
Monaco Asset Management
Monaco
-$314K
2
YIH
Y-Intercept (HK)
Hong Kong
-$191K
3
Goldman Sachs
Goldman Sachs
New York
-$179K
4
Northern Trust
Northern Trust
Illinois
-$153K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$148K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$13.6K – – –
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$10.9K -$144K -6,650 -93%
SWM
28
SeaCrest Wealth Management
New York
$9.84K – – –
BPA
29
Beacon Pointe Advisors
California
$7.57K – – –
LCGC
30
Legacy Capital Group California
California
$7.57K – – –
CFM
31
Catalyst Funds Management
Australia
$6.81K – – –
TRCT
32
Tower Research Capital (TRC)
New York
$5.46K -$2.99K -138 -36%
Barclays
33
Barclays
United Kingdom
$4.57K -$8.86K -409 -67%
GG
34
Gleason Group
Kentucky
$4.54K – – –
Simplex Trading
35
Simplex Trading
Illinois
$3K +$2.92K +135 New
NFSG
36
Newbridge Financial Services Group
Florida
$2.27K – – –
NA
37
NewEdge Advisors
Louisiana
$1.93K – – –
Northwestern Mutual Wealth Management
38
Northwestern Mutual Wealth Management
Wisconsin
$1.89K +$1.43K +66 +388%
LFG
39
Larson Financial Group
Missouri
$1.06K +$1.02K +47 New
JP Morgan Chase
40
JP Morgan Chase
New York
$685 – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$606 – – –
HI
42
Harbour Investments
Wisconsin
$332 – – –
Osaic Holdings
43
Osaic Holdings
Arizona
$288 – – –
Fidelity Investments
44
Fidelity Investments
Massachusetts
$216 -$5.16K -238 -96%
SS
45
Sunbelt Securities
Texas
$179 – – –
AAP
46
Arax Advisory Partners
Colorado
$163 – – –
AAG
47
Armstrong Advisory Group
Massachusetts
$91 – – –
IA
48
IFP Advisors
Florida
$76 – – –
PD
49
Point72 (DIFC)
United Arab Emirates
$44 -$8.27K -382 -99%
Citigroup
50
Citigroup
New York
$33 -$3.62K -167 -99%
1
2
3 4

CUE Hedge Fund Activity: Q3 2024 in Review

50 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2024, worth a combined $10.5M — down 38% from $17.1M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CUE and 3 opened new positions — a net loss of 25 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was Bleichroeder LP, adding an estimated $1.54M. The largest seller was Monaco Asset Management, exiting entirely with an estimated $314K sold.

  • 50 institutional investors held Cue Biopharma (CUE) as of Q3 2024, down from 75 in Q2 2024.
  • Funds reported $10.5M of Cue Biopharma stock for Q3 2024, down 38% quarter-over-quarter.
  • 3 funds opened new Cue Biopharma positions in Q3 2024 and 28 closed out, a net change of -25 holders.
  • The largest Cue Biopharma buyer in Q3 2024 was Bleichroeder LP, an estimated $1.54M added.
  • The largest Cue Biopharma seller in Q3 2024 was Monaco Asset Management, an estimated $314K sold.

Based on aggregated 13F filings for Q3 2024.